Cancer Family
Hematopoietic and Lymphoid Cell Neoplasm
CI-CAN-00000023Explore in graph →
HematologicNon-malignant4,231 active trials98 approved drugs1,009 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000023Explore in graph →
Clinical trials
18,680 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06451861 | Randomized Study of ABC-14 Regimen Compared With "3+7" Standard Induction Therapy or AB-14 for ND AML | recruiting | Phase 2 | 240 | Guangdong Provincial People's HospitalOTHER | 1 | Nov 17, 2025 | clinicaltrials |
| NCT05643742 | A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies | recruiting | Phase 1 / Phase 2 | 120 | CRISPR Therapeutics AGINDUSTRY | 2 | Nov 14, 2025 | clinicaltrials |
| NCT06550141 | Emapalumab Prevention of CAR-T Cell Associated Toxicities | recruiting | Phase 2 | 28 | Marcela V. Maus, M.D.,Ph.D.OTHER | 1 | Nov 14, 2025 | clinicaltrials |
| NCT02143830 | HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy(RAFA) | recruiting | Phase 2 | 70 | Children's Hospital Medical Center, CincinnatiOTHER | 1 | Nov 12, 2025 | clinicaltrials |
| NCT03125642 | Auto Stem Cell Transplant for Lymphoma Patients | recruiting | Phase 2 | 150 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Nov 4, 2025 | clinicaltrials |
| NCT04496349 | A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL | recruiting | Phase 2 | 78 | Ascentage Pharma Group Inc.INDUSTRY | 1 | Nov 4, 2025 | clinicaltrials |
| NCT06569680 | Mosunetuzumab in Patients With Newly Diagnosed Extranodal Marginal Zone Lymphoma | recruiting | Phase 2 | 35 | Izidore Lossos, MDOTHER | 1 | Nov 3, 2025 | clinicaltrials |
| NCT07002216 | BrECADD Therapy in Stage 2 B-IV Hodgkin Lymphoma(BrECADD) | recruiting | Phase 2 | 48 | University of MiamiOTHER | 1 | Nov 3, 2025 | clinicaltrials |
| NCT05031897 | Two Step Haplo With Radiation Conditioning | recruiting | Phase 2 | 63 | Thomas Jefferson UniversityOTHER | 1 | Oct 30, 2025 | clinicaltrials |
| NCT06796998 | Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL) | recruiting | Phase 2 | 25 | Izidore Lossos, MDOTHER | 1 | Oct 28, 2025 | clinicaltrials |
| NCT05890352 | Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment | recruiting | Phase 2 | 227 | SWOG Cancer Research NetworkNETWORK | 1 | Oct 20, 2025 | clinicaltrials |
| NCT06520098 | A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)(Benefit VA) | recruiting | Phase 2 | 100 | VA Office of Research and DevelopmentFED | 1 | Oct 14, 2025 | clinicaltrials |
| NCT06265584 | Trial of 2 Step ATG for Prevention of Acute GVHD Post Allogeneic Stem Cell Transplant | recruiting | Phase 2 | 56 | University of Alabama at BirminghamOTHER | 1 | Oct 8, 2025 | clinicaltrials |
| NCT06315309 | Trial of 2 Step ATG for Acute GVHD Prevention Post Myeloablative Allogeneic Stem Cell Transplant | recruiting | Phase 2 | 29 | University of Alabama at BirminghamOTHER | 1 | Oct 8, 2025 | clinicaltrials |
| NCT07202052 | Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial (RATIONAL-PT) | recruiting | Phase 2 / Phase 3 | 900 | Monash UniversityOTHER | 1 | Oct 7, 2025 | clinicaltrials |
| NCT07202065 | Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Dosing Immunoglobulin (Dose Ig) | recruiting | Phase 2 / Phase 3 | 900 | Monash UniversityOTHER | 1 | Oct 7, 2025 | clinicaltrials |
| NCT07202078 | Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Starting Immunoglobulin (Start Ig) | recruiting | Phase 2 / Phase 3 | 900 | Monash UniversityOTHER | 1 | Oct 7, 2025 | clinicaltrials |
| NCT07202091 | Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Immunoglobulin Stopping or Extension (Stop Ig) | recruiting | Phase 2 / Phase 3 | 900 | Monash UniversityOTHER | 1 | Oct 7, 2025 | clinicaltrials |
| NCT07208981 | Orelabrutinib Combined With Zebetuzumab and Lenalidomide for the Treatment of Newly Diagnosed MZL | recruiting | Phase 2 | 169 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Oct 6, 2025 | clinicaltrials |
| NCT07209059 | PET-Adapted First-Line Therapy With Nivolumab for Advanced Hodgkin Lymphoma(FINISH-HL) | recruiting | Phase 2 | 30 | National Research Center for Hematology, RussiaNETWORK | 1 | Oct 6, 2025 | clinicaltrials |
| NCT06534060 | MB-105 in Patients With CD5 Positive T-cell Lymphoma | recruiting | Phase 2 | 46 | March Biosciences IncINDUSTRY | 1 | Oct 3, 2025 | clinicaltrials |
| NCT05211570 | AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia | recruiting | Phase 1 / Phase 2 | 78 | AB ScienceINDUSTRY | 4 | Oct 2, 2025 | clinicaltrials |
| NCT07039877 | Efficacy of Low-dose Venetoclax With Itraconazole + TACL for R/R ALL Patients | recruiting | Phase 2 | 12 | Hospital Universitario Dr. Jose E. GonzalezOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT05932680 | Limited-duration Teclistamab | recruiting | Phase 2 | 75 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Oct 1, 2025 | clinicaltrials |
| NCT07199296 | Orelabrutinib and Rituximab With Optional Autologous Hematopoietic Stem Cell Transplantation in MCL Treatment | recruiting | Phase 2 | 45 | Ruijin HospitalOTHER | 1 | Sep 30, 2025 | clinicaltrials |
| NCT07195799 | Linperlisib Combination With Cyclophosphamide, Prednisone, and Thalidomide (CPT) in R/R NHL | recruiting | Phase 2 | 180 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Sep 29, 2025 | clinicaltrials |
| NCT04079179 | Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders(NACHO-COBI) | recruiting | Phase 2 | 90 | Carl AllenOTHER | 1 | Sep 18, 2025 | clinicaltrials |
| NCT05658640 | HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies(HEM-iSMART D) | recruiting | Phase 1 / Phase 2 | 26 | Princess Maxima Center for Pediatric OncologyOTHER | 15 | Sep 16, 2025 | clinicaltrials |
| NCT05698147 | Selinexor in Combination With MTX+Ritu to Treat R/R CNSL | recruiting | Phase 1 / Phase 2 | 30 | Tong Chen, MDOTHER | 1 | Sep 16, 2025 | clinicaltrials |
| NCT05745714 | HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies(HEM-iSMART C) | recruiting | Phase 1 / Phase 2 | 26 | Princess Maxima Center for Pediatric OncologyOTHER | 14 | Sep 16, 2025 | clinicaltrials |
| NCT05751044 | HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies(HEM-iSMART B) | recruiting | Phase 1 / Phase 2 | 26 | Princess Maxima Center for Pediatric OncologyOTHER | 14 | Sep 16, 2025 | clinicaltrials |
| NCT05305859 | Venetoclax Combining Chidamide and Azacitidine (VCA) in the Treatment of R/R AML | recruiting | Phase 2 | 30 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Sep 11, 2025 | clinicaltrials |
| NCT04150497 | Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01) | recruiting | Phase 1 / Phase 2 | 52 | Cellectis S.A.INDUSTRY | 2 | Sep 9, 2025 | clinicaltrials |
| NCT04385290 | Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC)(MOSAIC) | recruiting | Phase 1 / Phase 2 | 214 | Technische Universität DresdenOTHER | 1 | Sep 8, 2025 | clinicaltrials |
| NCT07159620 | Venetoclax Combined With Azacitidine, Chidamide, Vindesine, and Dexamethasone in Newly Diagnosed ETP-ALL Like Patients | recruiting | Phase 2 | 27 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Sep 8, 2025 | clinicaltrials |
| NCT05372354 | A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 260 | Bristol-Myers SquibbINDUSTRY | 5 | Sep 5, 2025 | clinicaltrials |
| NCT06160843 | Pembrolizumab and Olaparib Treatment for Relapsed or Refractory Peripheral T-Cell Lymphoma(POLAR) | recruiting | Phase 2 | 24 | National Cancer Centre, SingaporeOTHER | 1 | Sep 5, 2025 | clinicaltrials |
| NCT06382168 | DFP-10917 in Combination With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia | recruiting | Phase 1 / Phase 2 | 39 | Delta-Fly Pharma, Inc.INDUSTRY | 1 | Sep 3, 2025 | clinicaltrials |
| NCT03850574 | Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia(TUSCANY) | recruiting | Phase 1 / Phase 2 | 240 | Aptose Biosciences Inc.INDUSTRY | 6 | Aug 26, 2025 | clinicaltrials |
| NCT06855810 | Newly-diagnosed Pediatric T-cell ALL Protocol(CCCG-TALL-2025) | recruiting | Phase 2 / Phase 3 | 610 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 2 | Aug 26, 2025 | clinicaltrials |
| NCT06882057 | Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol(CCCG-LR-B-ALL) | recruiting | Phase 2 / Phase 3 | 3,000 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 2 | Aug 26, 2025 | clinicaltrials |
| NCT05607420 | Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma(NatHaLi-01) | recruiting | Phase 1 / Phase 2 | 80 | Cellectis S.A.INDUSTRY | 3 | Aug 24, 2025 | clinicaltrials |
| NCT06616389 | Study of ODX (OsteoDex) in Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 12 | DexTech Medical ABINDUSTRY | 1 | Aug 19, 2025 | clinicaltrials |
| NCT06664411 | Pola-ZR2P in Previously Untreated DLBCL | recruiting | Phase 2 | 80 | Navy General Hospital, BeijingOTHER | 1 | Aug 19, 2025 | clinicaltrials |
| NCT07078500 | Orelabrutinib Combined With Pola-R-CHP Regimen for the Treatment of Untreated Non-GCB Diffuse Large B-Cell Lymphoma | recruiting | Phase 2 | 48 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Aug 19, 2025 | clinicaltrials |
| NCT05565807 | Safety and Efficacy Study of An Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 84 | Zhejiang ACEA Pharmaceutical Co. Ltd.INDUSTRY | 1 | Aug 15, 2025 | clinicaltrials |
| NCT07124936 | A Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma | recruiting | Phase 1 / Phase 2 | 97 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 15, 2025 | clinicaltrials |
| NCT03765177 | CLIC-1901 for the Treatment of Patients With Relapsed/Refractory CD19 Positive Hematologic Malignancies(CLIC-01) | recruiting | Phase 1 / Phase 2 | 60 | Ottawa Hospital Research InstituteOTHER | 1 | Aug 14, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Nov 17, 2025source: clinicaltrials